library.onepin.app/vesugen Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Bioregulators

Bioregulators Bioregulator Not FDA-approved · investigational

Vesugen

Vesugen (Khavinson)

Bioregulator

Vesugen (Lys-Glu-Asp, or KED tripeptide) is a synthetic bioregulatory peptide developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a short-chain tripeptide designed to target the vascular endothelium and support blood vessel function. Vesugen is part of the Khavinson bioregulator family of peptides, which are proposed to regulate gene expression in specific tissues.,Vesugen is intended to normalize vascular wall function by acting on endothelial cells lining blood vessels. According to Khavinson's research, the KED sequence interacts with specific DNA promoter regions in vascular endothelial cells, modulating expression of genes involved in vascular tone, endothelial repair, and anti-thrombotic function. It is primarily used in the context of cardiovascular support and age-related vascular decline.,Like other Khavinson bioregulators, Vesugen is available as both an injectable peptide and an oral capsule form (Ventfort is the brand name of the capsule version derived from animal vascular tissue). It is used clinically in Russia but has not undergone FDA review or been approved for clinical use in Western countries. Published research comes predominantly from Russian academic institutions associated with Khavinson's research group.

Quick Start
Route
Subcutaneous (SubQ)
Start low
1-10mg
Frequency
daily
Timing
No specific requirement

SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
1-10mg · Subcutaneous (SubQ) · daily
Lowest starting point. Hold about a week to assess tolerance before stepping up.
1-10mg
daily
Standard
Vascular Elasticity
10-20 mg · Oral · Daily
animal study · Sokolova et al., Advances in Gerontology, 2016 - 'The effect of vascular peptide bioregulator on microcirculation in the brain cortex of old rats'
10-20 mg
Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Proposed to act as a gene-regulatory peptide that penetrates cell membranes and interacts with DNA promoter sequences in vascular endothelial cells, modulating expression of genes involved in endothelial nitric oxide synthase (eNOS), prostacyclin production, and vessel wall structural proteins.,May support vascular homeostasis by promoting endothelial cell proliferation and repair while reducing endothelial dysfunction markers. Khavinson's research suggests short peptides can epigenetically regulate tissue-specific gene expression patterns.,The tripeptide sequence (Lys-Glu-Asp) is proposed to have specificity for vascular tissue based on computational modeling of peptide-DNA interactions, distinguishing it from other bioregulators that target different organs.

Proposed to act as a gene-regulatory peptide that penetrates cell membranes and interacts with DNA promoter sequences in vascular endothelial cells, modulating expression of genes involved in endothelial nitric oxide synthase (eNOS), prostacyclin production, and vessel wall structural proteins.,May support vascular homeostasis by promoting endothelial cell proliferation and repair while reducing endothelial dysfunction markers. Khavinson's research suggests short peptides can epigenetically regulate tissue-specific gene expression patterns.,The tripeptide sequence (Lys-Glu-Asp) is proposed to have specificity for vascular tissue based on computational modeling of peptide-DNA interactions, distinguishing it from other bioregulators that target different organs.

02

What to expect

Early
Days 1–7

Days 1-7: Peptide-DNA interactions proposed to begin modulating gene expression in vascular endothelial cells. No subjective changes expected.

03

Evidence

HumanPresent
AnimalPresent
In-vitroPresent
2013Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results · Khavinson VKh, Kuznik BI, Ryzhak GA, Advances in Gerontology ↗review
2013Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies · Khavinson VKh, Kuznik BI, Ryzhak GA, Advances in Gerontology ↗review
2010Peptide bioregulation of aging: results and prospects · Anisimov VN, Khavinson VKh, Biogerontology ↗review
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Keep separate

CJC-1295 with DACDo not mix in same syringe.
05

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~0.15 hrs (5-15 minutes - tiny peptide)
Peak · Tmax
~15-30 min SubQ
Elimination
~1-2 hours
Activity
~60 days post-cycle (epigenetic vascular gene expression changes persist weeks to months per Khavinson theory)

Storage. Store refrigerated at 2-8C. Reconstituted solution should be used within 14-28 days.

06

Regulatory status

Used clinically in Russia. Not FDA-approved. Classified as a research compound in the US and EU. Oral equivalent (Ventfort) available as a supplement in some markets.

Put it to work

Calculate, log & track

Open Vesugen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Vesugen in the app →

Go deeper

The guide & community

The complete Vesugen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community